The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial

Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):46-51. doi: 10.1016/j.numecd.2014.07.012. Epub 2014 Aug 1.

Abstract

Background and aims: Despite strong mechanistic data, and promising results from in vitro and animal studies, the ability of probiotic bacteria to improve blood pressure and serum lipid concentrations in humans remains uncertain. The aim of this study was to determine the effect of Lactobacillus acidophilus La5 and Bifidobacterium animalis subsp lactis Bb12, provided in either yoghurt or capsule form, on home blood pressure and serum lipid profile.

Methods and results: Following a 3-week washout period, 156 overweight men and women over 55 y were randomized to a 6-week double-blinded, factorial, parallel study. The four intervention groups were: A) probiotic yoghurt plus probiotic capsules; B) probiotic yoghurt plus placebo capsules; C) control milk plus probiotic capsules; and D) control milk plus placebo capsules. Each probiotic test article provided a minimum L. acidophilus La5 and B. animalis subsp. lactis Bb12 dose of 3.0 × 10⁹ CFU/d. Home blood pressure monitoring, consisting of 7-day bi-daily repeat measurements, were collected at baseline and week 6. Fasting total cholesterol, low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), and serum triglyceride were performed at baseline and week 6. When compared to control milk, probiotic yoghurt did not significantly alter blood pressure, heart rate or serum lipid concentrations (P > 0.05). Similarly, when compared to placebo capsules, supplementation with probiotic capsules did not alter blood pressure or concentrations of total cholesterol LDLC, HDLC, or triglycerides (P > 0.05).

Conclusions: The probiotic strains L. acidophilus La5 and B. animalis subsp. lactis Bb12 did not improve cardiovascular risk factors.

Keywords: Blood pressure; Cholesterol; Dairy; Lipid; Probiotics; Yoghurt.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antithyroid Agents / administration & dosage
  • Antithyroid Agents / therapeutic use*
  • Bifidobacterium / growth & development
  • Body Mass Index
  • Cohort Studies
  • Double-Blind Method
  • Female
  • Humans
  • Hyperlipidemias / epidemiology
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control*
  • Hypertension / epidemiology
  • Hypertension / etiology
  • Hypertension / prevention & control*
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / therapeutic use*
  • Lactobacillus acidophilus / growth & development
  • Lipids / blood
  • Male
  • Middle Aged
  • Overweight / blood
  • Overweight / diet therapy*
  • Overweight / physiopathology
  • Probiotics / administration & dosage
  • Probiotics / therapeutic use*
  • Risk Factors
  • Western Australia / epidemiology
  • Yogurt / microbiology*

Substances

  • Antithyroid Agents
  • Hypolipidemic Agents
  • Lipids

Associated data

  • ANZCTR/ACTRN12612000033842